Table 1 Clinical characteristics of the study population.

From: Optical Genome Mapping in MDS and AML as tool for structural variant profiling—comment and data update on Yang et al.: “High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance”

Gender

 Female

18

 Male

24

Age median/years (range)

61 (21–75)

Diagnosis

 AML (n)

23

 AML from prior MDS /AML-MRC (n)

12

 MDS (n)

7

Risk classification

 ELN 2017

 

  Good (n)

6

  Intermediate (n)

13

  Poor (n)

15

 IPSS-Score

 

  Very high (n)

3

  High (n)

3

  Intermediate (n)

1

  1. Due to the inclusion prior to the novel world health organization (WHO) classification and European Leukemia Net (ELN) risk groups, here WHO2016 and ELN 2017 classifications are still used.
Back to article page